Cargando…
Effects of Switching from Anti-VEGF Treatment to Triamcinolone Acetonide in Eyes with Refractory Macular Edema Associated with Diabetic Retinopathy or Retinal Vein Occlusion
PURPOSE: To evaluate the efficacy of switching from intravitreal antivascular endothelial growth factor (VEGF) agents to triamcinolone acetonide (TA) in eyes with diabetic macular edema (DME) or with retinal vein occlusion-associated macular edema (RVO-ME) on the resolution of the macular edema (ME)...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695504/ https://www.ncbi.nlm.nih.gov/pubmed/33274211 http://dx.doi.org/10.1155/2020/4529850 |
_version_ | 1783615203165863936 |
---|---|
author | Tatsumi, Tomoaki Oshitari, Toshiyuki Baba, Takayuki Takatsuna, Yoko Yamamoto, Shuichi |
author_facet | Tatsumi, Tomoaki Oshitari, Toshiyuki Baba, Takayuki Takatsuna, Yoko Yamamoto, Shuichi |
author_sort | Tatsumi, Tomoaki |
collection | PubMed |
description | PURPOSE: To evaluate the efficacy of switching from intravitreal antivascular endothelial growth factor (VEGF) agents to triamcinolone acetonide (TA) in eyes with diabetic macular edema (DME) or with retinal vein occlusion-associated macular edema (RVO-ME) on the resolution of the macular edema (ME). METHODS: The medical records of 11 eyes of 11 patients with DME and 9 eyes of 9 patients with RVO-ME whose MEs were refractory to anti-VEGF treatment were reviewed. The central retinal thickness (CRT), best-corrected visual acuity (BCVA), intraocular pressure (IOP), and the mean interval of the recurrences were measured during the anti-VEGF treatment and after switching to the TA injections. RESULTS: Switching to TA injections significantly increased the mean interval for recurrences from 9.2 ± 2.7 weeks to 22.3 ± 12.9 weeks in eyes with DME (P = 0.006). In eyes with RVO-ME, the mean period of recurrence was 12.3 ± 5.6 weeks before and 11.6 ± 4.4 weeks after the switch (P = 0.44). The mean interval for recurrence was extended to more than 8 weeks in 7 of 11 eyes with DME, but none of the eyes with RVO-ME had a prolongation of more than 4 weeks. An elevation of the IOP was observed in 3 of the 20 eyes after the TA injection. CONCLUSIONS: These findings indicate that switching to TA injections can be a good option for DME eyes refractory to anti-VEGF injections but not for the RVO-ME eyes. |
format | Online Article Text |
id | pubmed-7695504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-76955042020-12-02 Effects of Switching from Anti-VEGF Treatment to Triamcinolone Acetonide in Eyes with Refractory Macular Edema Associated with Diabetic Retinopathy or Retinal Vein Occlusion Tatsumi, Tomoaki Oshitari, Toshiyuki Baba, Takayuki Takatsuna, Yoko Yamamoto, Shuichi Biomed Res Int Research Article PURPOSE: To evaluate the efficacy of switching from intravitreal antivascular endothelial growth factor (VEGF) agents to triamcinolone acetonide (TA) in eyes with diabetic macular edema (DME) or with retinal vein occlusion-associated macular edema (RVO-ME) on the resolution of the macular edema (ME). METHODS: The medical records of 11 eyes of 11 patients with DME and 9 eyes of 9 patients with RVO-ME whose MEs were refractory to anti-VEGF treatment were reviewed. The central retinal thickness (CRT), best-corrected visual acuity (BCVA), intraocular pressure (IOP), and the mean interval of the recurrences were measured during the anti-VEGF treatment and after switching to the TA injections. RESULTS: Switching to TA injections significantly increased the mean interval for recurrences from 9.2 ± 2.7 weeks to 22.3 ± 12.9 weeks in eyes with DME (P = 0.006). In eyes with RVO-ME, the mean period of recurrence was 12.3 ± 5.6 weeks before and 11.6 ± 4.4 weeks after the switch (P = 0.44). The mean interval for recurrence was extended to more than 8 weeks in 7 of 11 eyes with DME, but none of the eyes with RVO-ME had a prolongation of more than 4 weeks. An elevation of the IOP was observed in 3 of the 20 eyes after the TA injection. CONCLUSIONS: These findings indicate that switching to TA injections can be a good option for DME eyes refractory to anti-VEGF injections but not for the RVO-ME eyes. Hindawi 2020-11-20 /pmc/articles/PMC7695504/ /pubmed/33274211 http://dx.doi.org/10.1155/2020/4529850 Text en Copyright © 2020 Tomoaki Tatsumi et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Tatsumi, Tomoaki Oshitari, Toshiyuki Baba, Takayuki Takatsuna, Yoko Yamamoto, Shuichi Effects of Switching from Anti-VEGF Treatment to Triamcinolone Acetonide in Eyes with Refractory Macular Edema Associated with Diabetic Retinopathy or Retinal Vein Occlusion |
title | Effects of Switching from Anti-VEGF Treatment to Triamcinolone Acetonide in Eyes with Refractory Macular Edema Associated with Diabetic Retinopathy or Retinal Vein Occlusion |
title_full | Effects of Switching from Anti-VEGF Treatment to Triamcinolone Acetonide in Eyes with Refractory Macular Edema Associated with Diabetic Retinopathy or Retinal Vein Occlusion |
title_fullStr | Effects of Switching from Anti-VEGF Treatment to Triamcinolone Acetonide in Eyes with Refractory Macular Edema Associated with Diabetic Retinopathy or Retinal Vein Occlusion |
title_full_unstemmed | Effects of Switching from Anti-VEGF Treatment to Triamcinolone Acetonide in Eyes with Refractory Macular Edema Associated with Diabetic Retinopathy or Retinal Vein Occlusion |
title_short | Effects of Switching from Anti-VEGF Treatment to Triamcinolone Acetonide in Eyes with Refractory Macular Edema Associated with Diabetic Retinopathy or Retinal Vein Occlusion |
title_sort | effects of switching from anti-vegf treatment to triamcinolone acetonide in eyes with refractory macular edema associated with diabetic retinopathy or retinal vein occlusion |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695504/ https://www.ncbi.nlm.nih.gov/pubmed/33274211 http://dx.doi.org/10.1155/2020/4529850 |
work_keys_str_mv | AT tatsumitomoaki effectsofswitchingfromantivegftreatmenttotriamcinoloneacetonideineyeswithrefractorymacularedemaassociatedwithdiabeticretinopathyorretinalveinocclusion AT oshitaritoshiyuki effectsofswitchingfromantivegftreatmenttotriamcinoloneacetonideineyeswithrefractorymacularedemaassociatedwithdiabeticretinopathyorretinalveinocclusion AT babatakayuki effectsofswitchingfromantivegftreatmenttotriamcinoloneacetonideineyeswithrefractorymacularedemaassociatedwithdiabeticretinopathyorretinalveinocclusion AT takatsunayoko effectsofswitchingfromantivegftreatmenttotriamcinoloneacetonideineyeswithrefractorymacularedemaassociatedwithdiabeticretinopathyorretinalveinocclusion AT yamamotoshuichi effectsofswitchingfromantivegftreatmenttotriamcinoloneacetonideineyeswithrefractorymacularedemaassociatedwithdiabeticretinopathyorretinalveinocclusion |